Biosimilar Pipeline Analysis Market is Estimated to Witness High Growth Owing to Rise in Biosimilars Approvals

The biosimilar pipeline analysis market involves complex product development processes and regulatory requirements. Biosimilars are biologic medicines that are developed to have similar quality, safety and efficacy as an approved biologic medicine. The development of biosimilars can help lower healthcare costs by increasing patient access to critical biologic treatments through competition. As many blockbuster biologic drugs are expected to go off-patent over the next decade, it provides significant opportunity for biosimilar manufacturers to commercialize lower-cost alternatives. This has led to an increase in research activities in biosimilars. The Global biosimilar pipeline analysis Market is estimated to be valued at US$ 29.4 Bn in 2024 and is expected to exhibit a CAGR of 17% over the forecast period 2023 to 2030. Key Takeaways - Key players operating in the biosimilar pipeline analysis are Pfizer Inc. (AC. Hospira), Celltrion Inc, Pfizer Inc. (AC. Hospira), 3SBio Inc, Merck & Co, Inc, Biogen Inc and Samsung Bioepis. - Key opportunities in the market include rising demand for affordable biologics and biosimilars approvals in emerging markets. - Increase in biosimilars approvals worldwide is expected to drive market growth owing to cost effectiveness of biosimilars over reference biologics. Market Drivers The key driver boosting the biosimilar pipeline analysis market growth is increasing patent expiries of blockbuster biologics. Many top selling biologic drugs facing patent expiration over the forecast period providing opportunity for biosimilar manufacturers to launch affordable alternatives. This is encouraging pharmaceutical players to invest aggressively in development of biosimilars which is positively impacting the market growth.

Current challenges in biosimilar pipeline analysis market The biosimilar pipeline analysis market is facing several challenges currently which can hamper its growth potential. One of the major challenges is intellectual property barriers posed by reference drug manufacturers. Many large pharmaceutical companies actively lobby to extend and strengthen patent protection for their biologics to avoid biosimilar competition. The development of complex biosimilars requiring state-of-the-art technologies also poses a significant challenge due to high investment needed. Ensuring therapeutic equivalence of biosimilars with the reference biologic through comprehensive comparability assessment is another challenge area. Regulatory ambiguities across countries regarding approval pathway and interchangeability criteria for certain classes of biosimilars also create uncertainties. SWOT Analysis Strength: Biosimilars provide more treatment options at lower costs compared to costly biologics. They can potentially save billions of dollars for the healthcare systems. Weakness: Demonstrating biosimilarity and interchangeability is a complex scientific and regulatory challenge requiring high R&D investments. The IP environment also poses barriers. Opportunity: As patents of major biologics expire, biosimilars can target therapy areas of oncology, immunology and endocrinology which are growing markets. The increasing acceptance of biosimilars in developing countries also creates opportunities. Threats: Aggressive marketing and lobbying by reference drug manufacturers can delay market entry of biosimilars. Supply chain issues due to COVID-19 pandemic also threaten availability of biosimilars. In terms of value, North America dominates the current biosimilar pipeline analysis market owing to established regulatory pathways. The U.S. market alone accounts for over 30% of global market share and is expected to retain dominance through 2030. Europe is another major regional market with favorable biosimilar approval regulations and increasing uptake. Asia Pacific region is projected to be the fastest growing market during the forecast period driven by initiatives to promote affordable biologics in countries like China, India and South Korea. The Asia Pacific regional market witnessed the fastest growth during the historical period and is anticipated to retain its tag of highest growing market. This can be attributed to factors like large patient population, increasing healthcare expenditures, growing biologics market and supportive regulations. Countries like China, India and South Korea are expected to spearhead growth in the Asia Pacific biosimilar pipeline analysis market owing to focus on developing biosimilar industries and improving access to biologic drugs.

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/